Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AIML (OTCQB:AIMLF) said its subsidiary Neural Cloud entered a distribution agreement with Chile-based Intelimed on Feb 18, 2026 to commercialize MaxYield™, CardioYield™, and Insight360™ across Latin America. Intelimed is exclusive in Chile and non-exclusive elsewhere, targeting hospitals, clinics, OEMs, telemedicine providers and research institutions.
The partnership aims to expand access to AI-driven cardiac software, leveraging Intelimed's regional engagements and platform that aggregates FDA- and CE-authorized diagnostic tools.
AI/ML Innovations (OTCQB:AIMLF) subsidiary NeuralCloud signed a non-binding agreement with Movesense on February 11, 2026 to pilot AI-powered 1-lead ECG and Holter reporting in a third-party health system and affiliated clinics. The pilot will deploy NeuralCloud's MaxYield™ and CardioYield™ platforms alongside Movesense wearable hardware for operational validation and potential commercial rollout.
The collaboration focuses on increasing ECG screening reach, standardizing reporting, and scaling ambulatory monitoring capacity without materially increasing clinical workload; future commercialization depends on pilot results, definitive agreements, and regulatory considerations.
Neural Cloud, a wholly owned subsidiary of AI/ML Innovations (OTCQB:AIMLF), retained U.S. sales recruiter Commission Wolf on February 9, 2026 to build a U.S. commercial sales infrastructure for MaxYield™ and CardioYield™.
The agreement targets recruitment of 1099 independent sales representatives with cardiology relationships to support market entry as regulatory milestones are met and to accelerate pilot-to-commercial conversions.
AI/ML Innovations (OTCQB:AIMLF) appointed Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board, effective January 28, 2026. The move follows his months-long collaboration on AIML's MaxYield™, CardioYield™, and Insight360™ platforms and aims to support clinical validation, regulatory engagement, and global deployment.
This leadership transition succeeds Peter Kendall and reinforces the company’s focus on arrhythmia care, ambulatory monitoring, and AI-driven ECG diagnostics as AIML advances clinical studies and market-readiness.
AI/ML Innovations (AIMLF) subsidiary NeuralCloud announced a strategic collaboration with Movesense to bundle Movesense single-lead wearable ECG sensors with NeuralCloud's AI platforms MaxYield, CardioYield, and Insight360.
The partnership targets clinical, research, wellness, and performance markets and positions lower-cost, wearable Holter-style monitoring workflows with scalable AI-driven signal enhancement and report generation.
NeuralCloud Solutions (AIMLF) signed a non-binding commercial term sheet with Lakeshore Cardiology on Dec 12, 2025 to deploy CardioYield™ (powered by patent-pending MaxYield™) for AI-driven Holter and ambulatory ECG analysis. The agreement defines a staged rollout: internal validation with representative Holter files, a limited paid trial in clinical workflows, system integration and cloud setup, and commercial availability pending Health Canada clearance. CardioYield™ produces beat-by-beat, machine-readable PQRST labeling and end-to-end Holter reporting.
AI/ML Innovations (AIMLF) appointed Erik Suokas as Chief Operating Officer effective January 7, 2026 to accelerate commercial execution and operational scale as the company transitions from platform validation to revenue and customer delivery.
Suokas will oversee commercial strategy, contract discipline, delivery readiness, and cross-functional alignment, working with the CEO and Chief Product Officer to convert growing commercial momentum into repeatable revenue. The release highlights his >20 years of healthcare and MedTech leadership and cites ~200% revenue growth in under two years while launching a Canadian direct-sales organization at a prior employer.
AI/ML Innovations (CSE:AIML | OTCQB:AIMLF) announced leadership changes effective December 29, 2025. The company's consulting agreement with Campfire Properties concluded and Peter Kendall is no longer serving as President and Chief Commercial Officer.
Paul Duffy, CEO and Chairman, will assume the additional role of President. The board thanked Mr. Kendall for his service.
AI/ML Innovations (OTCQB:AIMLF) will host a livestream shareholder update with Chairman & CEO Paul Duffy on December 18, 2025 at 4:00 PM ET. The presentation will review 2025 milestones, outline commercialization progress and pilot programs, and preview the company's first-90-day priorities for 2026, including regulatory pathway advancement. Shareholders may attend via Zoom and pre-submit questions to Ask@aiml.health.
AI/ML Innovations (OTC:AIMLF) has engaged Guerilla Capital to provide investor relations, communications, and investor outreach services.
The engagement starts immediately for an initial term of 12 months at an aggregate fee of Cdn$120,000. Cdn$30,000 is payable up front and the remaining Cdn$90,000 is payable in three quarterly installments of Cdn$30,000. The agreement may be terminated any time after the initial three months.